Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne Mortimer

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in CaliforniaYuan Chun Ding, Rosalyn W Sayaman, Denise Wolf, et al.
The Oncologist|September 4, 2009
Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologistsArti Hurria, F Lennie Wong, Sumanta Pal, et al.
Research Square|July 10, 2026
Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohortVeronica Jones, Yongzhe Wang, Christine Quinones, et al.
Breast Cancer Research and Treatment|November 12, 2014
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapyJoanne Mortimer, Jae Jung, Yuan Yuan, et al.
Investigational New Drugs|June 12, 2020
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumorsCharlotte Lemech, Natasha Woodward, Nancy Chan, et al.
Scientific Reports|November 26, 2020
Towards integration of <sup>64</sup>Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancerAngela M Jarrett, David A Hormuth, Vikram Adhikarla, et al.
Brain, Behavior, & Immunity - Health|August 28, 2023
Inflammation-related proteins as biomarkers of treatment-related behavioral symptoms: A longitudinal study of breast cancer patients and age-matched controlsSunita K Patel, Elizabeth C Breen, I Benjamin Paz, et al.
The Oncologist|March 21, 2023
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast CancerXuan Ge, Carolyn E Behrendt, Susan E Yost, et al.
Journal of the American College of Surgeons|August 16, 2014
Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National Comprehensive Cancer Network institutionsBeryl McCormick, Rebecca A Ottesen, Melissa E Hughes, et al.
Frontiers in Oncology|April 2, 2021
Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot StudyChi Wah Wong, Susan E Yost, Jin Sun Lee, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Characterization of the somatic landscape and transcriptional profile of breast tumors from 748 Hispanic/Latina women in CaliforniaYuan Chun Ding, Rosalyn W Sayaman, Denise Wolf, et al.
The Oncologist|September 4, 2009
Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologistsArti Hurria, F Lennie Wong, Sumanta Pal, et al.
Research Square|July 10, 2026
Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohortVeronica Jones, Yongzhe Wang, Christine Quinones, et al.
Breast Cancer Research and Treatment|November 12, 2014
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapyJoanne Mortimer, Jae Jung, Yuan Yuan, et al.
Investigational New Drugs|June 12, 2020
A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumorsCharlotte Lemech, Natasha Woodward, Nancy Chan, et al.
Scientific Reports|November 26, 2020
Towards integration of <sup>64</sup>Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancerAngela M Jarrett, David A Hormuth, Vikram Adhikarla, et al.
Brain, Behavior, & Immunity - Health|August 28, 2023
Inflammation-related proteins as biomarkers of treatment-related behavioral symptoms: A longitudinal study of breast cancer patients and age-matched controlsSunita K Patel, Elizabeth C Breen, I Benjamin Paz, et al.
The Oncologist|March 21, 2023
Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast CancerXuan Ge, Carolyn E Behrendt, Susan E Yost, et al.
Journal of the American College of Surgeons|August 16, 2014
Impact of guideline changes on use or omission of radiation in the elderly with early breast cancer: practice patterns at National Comprehensive Cancer Network institutionsBeryl McCormick, Rebecca A Ottesen, Melissa E Hughes, et al.
Frontiers in Oncology|April 2, 2021
Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot StudyChi Wah Wong, Susan E Yost, Jin Sun Lee, et al.
Pageof 11